A study of labetalol in patients of European, West Indian and West African origin.
1 Hypertension in  West Indians and Africans is common and has an unacceptably high mortality in the younger patients. 2 Fifty-three patients received labetalol (a combined alpha- and beta-adrenoreceptor antagonist) as part of an open evaluation of its anti-hypertensive effect. Ten non-caucasian patients were included. 3 Significant reductions in systolic and diastolic pressures were obtained in the caucasian patients, the African and West Indian patients remaining refractory to therapy.
D000328:Adult; D000354:Africa, Western; D000368:Aged; D044383:Black People; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D004351:Drug Resistance; D004983:Ethanolamines / Q000627:therapeutic use*; D005060:Europe; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D007741:Labetalol / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D014900:West Indies; D044465:White People
D004983:Ethanolamines; D007741:Labetalol